{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:14:55Z","timestamp":1790270095418,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Hypoparathyroidism (HypoPT) is a relatively rare condition characterised by inadequately low levels of calcium and low levels of parathyroid hormone (PTH), or a complete absence of PTH. In consequence, the body loses its ability to correctly regulate the calcium and phosphate metabolism. Low calcium levels (hypocalcemia) and high phosphorus levels (hyperphosphataemia) are observed in the blood serum of patients. Conventional therapy remains the treatment of choice, involving calcium supplementation (most often calcium carbonate) and active forms of vitamin D, such as alfacalcidol or calcitriol. However, this treatment does not always provide optimal control of the disease or a satisfying quality of life for patients. In recent years, development of therapies using PTH analogues has been observed, as well as intensive research into new pharmacological strategies modulating the PTH\/PTH1R signalling pathway. The aim of this paper is to present the current state of knowledge on methods of treatment of hypoparathyroidism and to discuss the prospects for the development of new therapeutic strategies.<\/jats:p>","DOI":"10.3390\/jcm15197445","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:29:53Z","timestamp":1790267393000},"page":"7445","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary and Emerging Therapeutic Strategies in Hypoparathyroidism: From Conventional Treatment to Restoration of Parathyroid Function"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0001-7809","authenticated-orcid":false,"given":"Dominika","family":"Kochan-Olszewska","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Holycross Cancer Center, Artwi\u0144skiego 3, 25-734 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-5898","authenticated-orcid":false,"given":"Aldona","family":"Kowalska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Holycross Cancer Center, Artwi\u0144skiego 3, 25-734 Kielce, Poland"},{"name":"Collegium Medicum, Jan Kochanowski University in Kielce, 25-317 Kielce, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5603\/ep.96950","article-title":"Management of hypoparathyroidism: A Position Statement of the Expert Group of the Polish Society of Endocrinology","volume":"74","author":"Misiorowski","year":"2023","journal-title":"Endokrynol. Pol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/jbmr.4675","article-title":"Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism","volume":"37","author":"Bjornsdottir","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/jbmr.4714","article-title":"Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review","volume":"37","author":"Pasieka","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e210379","DOI":"10.1530\/EC-21-0379","article-title":"Low health-related quality of life in hypoparathyroidism and need for PTH analog","volume":"11","author":"Kontogeorgos","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results from the Phase 3 PaTHway Trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","article-title":"Renal complications in patients with chronic hypoparathyroidism on conventional therapy: A systematic literature review: Renal disease in chronic hypoparathyroidism","volume":"22","author":"Gosmanova","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and Safety of Parathyroid Hormone Replacement with TransCon PTH in Hypoparathyroidism: 26-Week Results from the Phase 3 PaTHway Trial","volume":"38","author":"Khan","year":"2023","journal-title":"J. Bone Miner. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"156335","DOI":"10.1016\/j.metabol.2025.156335","article-title":"Best practice recommendations for the diagnosis and management of hypoparathyroidism","volume":"171","author":"Khan","year":"2025","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J. Bone Min. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: A Canadian and International Consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of Hypoparathyroidism: Summary Statement and Guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/jbmr.4687","article-title":"Methodology for the Guidelines on Evaluation and Management of Hypoparathyroidism and Primary Hyperparathyroidism","volume":"37","author":"Yao","year":"2022","journal-title":"J. Bone Min. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of Hypoparathyroidism: Present and Future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"G49","DOI":"10.1093\/ejendo\/lvaf222","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults","volume":"193","author":"Bollerslev","year":"2025","journal-title":"Eur. J. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1743-7075-9-24","article-title":"Calcium affects on vascular endpoints","volume":"9","author":"Patel","year":"2012","journal-title":"Nutr. Metab."},{"key":"ref_17","unstructured":"Feingold, K.R., Adler, R.A., Ahmed, S.F., Anawalt, B., Blackman, M.R., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., and Dungan, K. (2026, June 26). Hypoparathyroidism and Pseudohypoparathyroidism, Endotext [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279165\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ecl.2018.07.012","article-title":"Conventional Treatment of Hypoparathyroidism","volume":"47","author":"Babey","year":"2018","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_19","first-page":"E313","article-title":"Nature of calcemic effect of 1,25-dihydroxyvitamin D3 in experimental hypoparathyroidism","volume":"244","author":"Hefti","year":"1983","journal-title":"Am. J. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197803162981101","article-title":"Treatment of hypoparathyroid patients with chlorthalidone","volume":"298","author":"Porter","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archpedi.1986.02140160057032","article-title":"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide","volume":"140","author":"Santos","year":"1986","journal-title":"Am. J. Dis. Child."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"bvaf113","DOI":"10.1210\/jendso\/bvaf113","article-title":"Switch from rhPTH1-84 to TransCon PTH with Individual Dose Adjustment in Adult Hypoparathyroidism\u20144-Week Results","volume":"9","author":"Siggelkow","year":"2025","journal-title":"J. Endocr. Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism","volume":"34","author":"Pihl","year":"2019","journal-title":"J. Bone Min. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.eprac.2025.08.008","article-title":"Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients with Hypoparathyroidism","volume":"31","author":"Graham","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s41687-024-00757-1","article-title":"Measuring treatment impacts on symptoms in adults with hypoparathyroidism: Findings from the PaTHway trial","volume":"8","author":"Brod","year":"2024","journal-title":"J. Patient-Rep. Outcomes"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, J., Hu, Z., Ma, Z., Feng, G., Zhang, L., Zhu, S., Hu, J., Han, W., and Li, T. (2026). Reflections on prevention and treatment of post-thyroidectomy hypoparathyroidism: Current management approaches and future prospects. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1768391"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1007\/s12325-025-03396-0","article-title":"Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism Using Multicriteria Decision Analysis (MCDA)","volume":"42","author":"Badia","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/MS9.0000000000004734","article-title":"Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug","volume":"88","author":"Shahid","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1210\/clinem\/dgae808","article-title":"MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial","volume":"110","author":"Carney","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102345","DOI":"10.1016\/j.molmet.2026.102345","article-title":"Discovery and characterization of canvuparatide, a once-weekly parathyroid hormone analog for the treatment of hypoparathyroidism","volume":"107","author":"Zhang","year":"2026","journal-title":"Mol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/clinem\/dgae121","article-title":"An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism","volume":"109","author":"Takacs","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40618-025-02760-9","article-title":"Unveiling the complexities of hypoparathyroidism: A comprehensive review of clinical manifestations, diagnosis, and novel therapies","volume":"49","author":"Cetani","year":"2026","journal-title":"J. Endocrinol. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"lvag096.144","DOI":"10.1093\/ejendo\/lvag096.144","article-title":"OC12.4\u2014LBA_ECE_1141\u2014The safety and efficacy of eneboparatide, a parathyroid hormone 1 receptor agonist, in adults with chronic hypoparathyroidism: A phase 3, randomized, placebo-controlled study (CALYPSO)","volume":"195","author":"Brandi","year":"2026","journal-title":"Eur. J. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2215\/CJN.05910809","article-title":"Calcium metabolism in health and disease","volume":"5","author":"Peacock","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/jbmr.3747","article-title":"Treatment of Autosomal Dominant Hypocalcemia Type 1 with the Calcilytic NPSP795 (SHP635)","volume":"34","author":"Roberts","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Roszko, K.L., Bi, R.D., and Mannstadt, M. (2016). Autosomal Dominant Hypocalcemia (Hypoparathyroidism) Types 1 and 2. Front. Physiol., 7.","DOI":"10.3389\/fphys.2016.00458"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ng1194-303","article-title":"Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation","volume":"8","author":"Pollak","year":"1994","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal Dominant Hypocalcemia Type 1: A Systematic Review","volume":"37","author":"Roszko","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_43","first-page":"831","article-title":"Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations","volume":"48","author":"David","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Miglietta, F., Palmini, G., Giusti, F., Donati, S., Aurilia, C., Iantomasi, T., and Brandi, M.L. (2021). Hypoparathyroidism: State of the Art on Cell and Tissue Therapies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910272"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2407567","DOI":"10.1002\/advs.202407567","article-title":"Induced Pluripotent Stem Cell-Derived Parathyroid Organoids Resemble Parathyroid Morphology and Function","volume":"11","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, D., Guo, L., Wu, J., Ning, N., and Chen, L. (2025). Progress and future prospects for the surgical treatment of permanent hypoparathyroidism after thyroid surgery: A narrative review. BMC Surg., 26.","DOI":"10.1186\/s12893-025-03413-7"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e13634","DOI":"10.1111\/cpr.13634","article-title":"Directed differentiation of human embryonic stem cells into parathyroid cells and establishment of parathyroid organoids","volume":"57","author":"Wang","year":"2024","journal-title":"Cell Prolif."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1507\/endocrj.EJ25-0069","article-title":"Generation of parathyroid glands from pluripotent stem cells","volume":"72","author":"Kano","year":"2025","journal-title":"Endocr. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.stemcr.2022.09.015","article-title":"Patient-derived parathyroid organoids as a tracer and drug-screening application model","volume":"17","author":"Noltes","year":"2022","journal-title":"Stem Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: Diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jbmr\/zjae049","article-title":"A delicate balance: The challenges of hypoparathyroidism","volume":"39","author":"Papaioannou","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"D\u00edez, J.J. (2020). Hypoparathyroidism: A brief historical overview for clinicians. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1769262"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s40618-026-02861-z","article-title":"Management of patients with hypoparathyroidism: A Delphi consensus analysis","volume":"49","author":"Cianferotti","year":"2026","journal-title":"J. Endocrinol. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-766","DOI":"10.12688\/f1000research.22717.1","article-title":"Recent advances in understanding and managing hypoparathyroidism","volume":"9","author":"Rubin","year":"2020","journal-title":"F1000Research"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7445\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:49:19Z","timestamp":1790268559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":55,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197445"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197445","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}